Dive into our repository of groundbreaking research papers, where we merge clinical expertise with data driven insights to revolutionize patient care and treatment strategies.
Explore the latest news about COTA, where our breakthroughs and collaborations lead the charge in transforming healthcare. Each mention underscores our role in pioneering data-driven solutions for real-world challenges.
NEW YORK–(BUSINESS WIRE)–COTA Inc., a leader in real-world data (RWD) and analytics for oncology, announces a new partnership with leading...
Findings to be Presented at the San Antonio Breast Cancer Symposium NEW YORK, Dec. 9, 2024 /PRNewswire/ — COTA Inc.,...
For over a decade, COTA has been tackling the most complicated cancer data to produce real-world data that can power...
NEW YORK–(BUSINESS WIRE)–COTA Inc., a leader in real-world data (RWD) and analytics for oncology, announces a new partnership with leading...
Findings to be Presented at the San Antonio Breast Cancer Symposium NEW YORK, Dec. 9, 2024 /PRNewswire/ — COTA Inc.,...
For over a decade, COTA has been tackling the most complicated cancer data to produce real-world data that can power...
Summary During this episode of Real World Talk, host Kevin Keogh talks with Dr. Andrew Pecora of OMI (Outcomes Matter…
Summary During this episode of Real World Talk, host Zoe Li has a conversation with Michelle Hoiseth, the Chief Data…
Explore impactful case studies that highlight COTA’s innovative solutions in action. These stories illustrate the significant differences our data driven approach makes in patient care and healthcare improvement.
Much of today’s investigational cancer therapeutics originates in small biotechnology companies, most of which are innovative and agile by nature, but also lack the financial horsepower, resources, and infrastructure of…
Real-world data (RWD) in Oncology proves to be a vital source for clinical decisions and program decisions. COTA partnered with a Top 5 Pharma company to curate a custom multiple…
Despite advances in liquid biopsies, standard-of-care remains tissue-based genotyping, an approach that is relatively invasive, inconvenient, slow, and expensive
…
